Prevention of ventricular fibrillation during hypothermia with bretylium tosylate.
D000769:Anesthesia, Inhalation; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D001949:Bretylium Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002245:Carbon Dioxide / Q000097:blood; D002395:Catecholamines / Q000378:metabolism; D004285:Dogs; D004562:Electrocardiography; D006221:Halothane; D006339:Heart Rate; D006470:Hemorrhage / Q000150:complications; D007036:Hypothermia, Induced / Q000009:adverse effects*; D007273:Injections, Intramuscular; D009206:Myocardium / Q000378:metabolism; D010100:Oxygen / Q000097:blood; D013564:Sympathetic Nervous System / Q000187:drug effects; D014693:Ventricular Fibrillation / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D001949:Bretylium Compounds; D002395:Catecholamines; D002245:Carbon Dioxide; D010100:Oxygen; D006221:Halothane